Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Poseida Therapeutics Added to Nasdaq Biotechnology Index

December 18, 2020
SAN DIEGO, CA - December 18, 2020 - Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with…
READ MORE

Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index

December 18, 2020
WALTHAM, MA - December 18, 2020 -  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has…
READ MORE

Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer

November 18, 2020
NEW YORK, NY – November 18, 2020 – Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a Series…
READ MORE